ClinicalTrials.gg
CompletedNCT02712008RUBYUpdated Oct 3, 2018Results posted

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

A Phase 2 interventional study of REGN910-3 and Intravitreal Aflibercept Injection (IAI) in Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-03.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
9th of 53
302 · median 49
Started
2016
with 8 others
Phase 2
7 of 53
none open now
Registered
29th of 53
by date
Lead sponsor
6 of 53
Regeneron Pharmaceuticals

Among the 53 studies testing aflibercept in Macular Edema, this one is the 9th largest by enrollment, is one of 9 that started in 2016, is one of 7 in phase 2, and was the 29th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Men or women ≥18 years of age with type 1 or type 2 diabetes mellitus who have DME with central involvement in the study eye
  2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the study eye
  3. Willing and able to comply with clinic visits and study-related procedures
  4. Provide signed

Key Exclusion Criteria:

  1. Evidence of macular edema due to any cause other than diabetes mellitus in either eye
  2. IVT anti-VEGF in the study eye within 12 weeks of the screening visit
  3. Panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening

Note: Other inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    REGN910-3 (3 mg: 2 mg)

    Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.

    Drug: REGN910-3

  • Experimental
    REGN910-3 (6 mg:2 mg)

    Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.

    Drug: REGN910-3

  • Active comparator
    Aflibercept 2 mg

    Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.

    Drug: Intravitreal Aflibercept Injection (IAI)

  • Experimental
    REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8

    Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.

    Drug: REGN910-3

  • Experimental
    REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12

    Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.

    Drug: REGN910-3

  • Experimental
    Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8

    Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.

    Drug: Intravitreal Aflibercept Injection (IAI)

  • Experimental
    Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12

    Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.

    Drug: Intravitreal Aflibercept Injection (IAI)

  • Experimental
    Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8

    Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.

    Drug: REGN910-3 · Drug: Intravitreal Aflibercept Injection (IAI)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 36.

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12

    Central Sub-field Retinal Thickness (CST) was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36

    CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 36.

    Time frame: Baseline, Week 36

  3. Percentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline

    The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).

    Time frame: Baseline, Week 12

  4. Percentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline

    The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).

    Time frame: Baseline, Week 36

07

Results

Posted Oct 3, 2018

Participant flow

The study was conducted at 70 sites in US. A total of 438 participants were screened in the study.

Baseline (Day 1) up to Week 12
Participant flow — Baseline (Day 1) up to Week 12
MilestoneREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mgREGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8
Started5010015200000
Completed469714800000
Not completed43400000
Withdrew: Death30000000
Withdrew: Withdrawal by subject02100000
Withdrew: Lost to follow-up10200000
Withdrew: Protocol violation00100000
Withdrew: Other unspecified01000000
From Week 12 up to Week 36
Participant flow — From Week 12 up to Week 36
MilestoneREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mgREGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8
Started45004452464849
Completed44004250464345
Not completed10022054
Withdrew: Adverse event00001002
Withdrew: Death10000010
Withdrew: Lost to follow-up00010010
Withdrew: Physician decision00011000
Withdrew: Withdrawal by subject00000032

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.

Time frame:
Baseline, Week 12
Reported as:
Mean · Letters correctly read
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12
Letters correctly readREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mg
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 126.8 ± 7.308.5 ± 6.898.8 ± 9.71
Statistical analysis
  • REGN910-3 (3 mg: 2 mg) vs Aflibercept 2 mg · ANCOVA · p = 0.1368 (Threshold for significance at 0.05 level.) · Least square mean difference: -2.09 · 95% CI - 4.84 to 0.67
  • REGN910-3 (6 mg:2 mg) vs Aflibercept 2 mg · ANCOVA · p = 0.9716 (Threshold for significance at 0.05 level.) · Least square mean difference: 0.04 · 95% CI - 2.10 to 2.18
PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 36.

Time frame:
Baseline, Week 36
Reported as:
Mean · Letters correctly read
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36
Letters correctly readREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8
Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 369.8 ± 9.9210.3 ± 8.208.5 ± 7.748.7 ± 10.6510.0 ± 10.3711.9 ± 12.01
Statistical analysis
  • REGN910-3 (3 mg: 2 mg) vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · ANCOVA · p = 0.1665 (Threshold for significance at 0.05 level.) · Least square mean difference: 2.15 · 95% CI -0.90 to 5.20
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · ANCOVA · p = 0.2223 (Threshold for significance at 0.05 level.) · Least square mean difference: 1.90 · 95% CI -1.16 to 4.95
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · ANCOVA · p = 0.7943 (Threshold for significance at 0.05 level.) · Least square mean difference: 0.39 · 95% CI -2.54 to 3.32
  • Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 · ANCOVA · p = 0.6655 (Threshold for significance at 0.05 level.) · Least square mean difference: 0.66 · 95% CI -2.35 to 3.67
  • Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 vs Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 · ANCOVA · p = 0.1278 (Threshold for significance at 0.05 level.) · Least square mean difference: 2.33 · 95% CI -0.67 to 5.33
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 vs REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 · ANCOVA · p = 0.3159 (Threshold for significance at 0.05 level.) · Least square mean difference: -1.51 · -1.51% CI -4.47 to 1.45
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 · ANCOVA · p = 0.8537 (Threshold for significance at 0.05 level.) · Least square mean difference: -0.27 · 95% CI -3.18 to 2.63
SecondaryChange From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12

Central Sub-field Retinal Thickness (CST) was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.

Time frame:
Baseline, Week 12
Reported as:
Mean · Microns
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12
MicronsREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mg
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12-169.4 ± 155.86-184.0 ± 143.69-174.6 ± 160.36
Statistical analysis
  • REGN910-3 (3 mg: 2 mg) vs Aflibercept 2 mg · ANCOVA · p = 0.1105 (Threshold for significance at 0.05 level.) · Least square mean difference: -24.43 · 95% CI -54.46 to 5.61
  • REGN910-3 (6 mg:2 mg) vs Aflibercept 2 mg · ANCOVA · p = 0.0183 (Threshold for significance at 0.05 level.) · Least square mean difference: -27.79 · 95% CI - 50.83 to - 4.74
SecondaryChange From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36

CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 36.

Time frame:
Baseline, Week 36
Reported as:
Mean · Microns
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36
MicronsREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8
Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36-210.4 ± 164.06-223.4 ± 145.35-193.7 ± 158.29-161.9 ± 125.99-210.6 ± 202.15-203.7 ± 163.08
Statistical analysis
  • REGN910-3 (3 mg: 2 mg) vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · ANCOVA · p = 0.0040 (Threshold for significance at 0.05 level.) · Least square mean difference: -55.91 · 95% CI - 93.81 to - 18.01
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · ANCOVA · p = 0.0365 (Threshold for significance at 0.05 level.) · Least square mean difference: -40.51 · 95% CI -78.46 to -2.57
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · ANCOVA · p = 0.0454 (Threshold for significance at 0.05 level.) · Least square mean difference: -37.15 · 95% CI -73.53 to -0.77
  • Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 · ANCOVA · p = 0.9266 (Threshold for significance at 0.05 level.) · Least square mean difference: 1.75 · 95% CI -35.54 to 39.03
  • Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 vs Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 · ANCOVA · p = 0.4116 (Threshold for significance at 0.05 level.) · Least square mean difference: -15.49 · 95% CI -52.58 to 21.59
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 vs REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 · ANCOVA · p = 0.8574 (Threshold for significance at 0.05 level.) · Least square mean difference: 3.36 · 95% CI -33.42 to 40.14
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 · ANCOVA · p = 0.0351 (Threshold for significance at 0.05 level.) · Least square mean difference: -38.90 · 95% CI -75.06 to -2.73
SecondaryPercentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline

The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline
Percentage of participantsREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mg
Percentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline13.321.315.2
Statistical analysis
  • REGN910-3 (3 mg: 2 mg) vs Aflibercept 2 mg · Cochran-Mantel-Haenszel · p = 0.7617 (Threshold for significance at 0.05 level.) · Difference in percentages: -1.8 · 95% CI -13.5 to 9.8
  • REGN910-3 (6 mg:2 mg) vs Aflibercept 2 mg · Cochran-Mantel-Haenszel · p = 0.2268 (Threshold for significance at 0.05 level.) · Difference in percentages: 6.1 · 95% CI - 4.1 to 16.3
SecondaryPercentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline

The Diabetic Retinopathy Disease Severity Scale (DRSS) was used to describe overall retinopathy severity. It measured the 5 levels of diabetic retinopathy ranging from absence of retinopathy to severe retinopathy (none, mild, moderate, severe, and proliferative).

Time frame:
Baseline, Week 36
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline
Percentage of participantsREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8
Percentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline26.734.134.026.125.535.4
Statistical analysis
  • REGN910-3 (3 mg: 2 mg) vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · Cochran-Mantel-Haenszel · p = 0.8896 (Threshold for significance at 0.05 level.) · Difference in percentages: -1.3 · 95% CI -20.4 to 17.7
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · Cochran-Mantel-Haenszel · p = 0.5021 (Threshold for significance at 0.05 level.) · Difference in percentages: 6.4 · 95% CI -12.6 to 25.5
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 · Cochran-Mantel-Haenszel · p = 0.5273 (Threshold for significance at 0.05 level.) · Difference in percentages: 6.0 · 95% CI -12.8 to 24.7
  • Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 · Cochran-Mantel-Haenszel · p = 0.8683 (Threshold for significance at 0.05 level.) · Difference in percentages: -1.5 · 95% CI -19.7 to 16.6
  • Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8 vs Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8 · Cochran-Mantel-Haenszel · p = 0.3546 (Threshold for significance at 0.05 level.) · Difference in percentages: 8.8 · 95% CI -9.8 to 27.4
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8 vs REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 · Cochran-Mantel-Haenszel · p = 0.9801 (Threshold for significance at 0.05 level.) · Difference in percentages: 0.2 · 95% CI -19.0 to 19.5
  • REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12 vs Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12 · Cochran-Mantel-Haenszel · p = 0.3528 (Threshold for significance at 0.05 level.) · Difference in percentages: 8.8 · 95% CI -9.9 to 27.4

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 36) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REGN910-3 (3 mg: 2 mg)5/50 (10%)6/50 (12%)18/50 (36%)
REGN910-3 (6 mg:2 mg)0/100 (0%)18/100 (18%)42/100 (42%)
Aflibercept 2 mg4/152 (2.6%)31/152 (20.4%)55/152 (36.2%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mg
DeathGeneral disorders2/500/1000/152
Cardiac failure congestiveCardiac disorders0/503/1003/152
Cardiac arrestCardiac disorders1/500/1000/152
CellulitisInfections and infestations1/501/1003/152
Diabetic foot infectionInfections and infestations1/500/1000/152
OsteomyelitisInfections and infestations1/501/1001/152
FallInjury, poisoning and procedural complications0/502/1001/152
Troponin increasedInvestigations1/500/1000/152
Cerebrovascular accidentNervous system disorders1/500/1000/152
Diabetic footSkin and subcutaneous tissue disorders1/500/1002/152
Most frequent other events
Showing 10 of 12
Most frequent other events
EventREGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mg
HypertensionVascular disorders4/5014/10019/152
Conjunctival haemorrhageEye disorders5/503/10013/152
Vitreous detachmentEye disorders1/508/1008/152
Blood pressure increasedInvestigations2/507/10010/152
CoughRespiratory, thoracic and mediastinal disorders0/507/1004/152
Eye painEye disorders3/503/1004/152
Viral upper respiratory tract infectionInfections and infestations3/503/1005/152
Musculoskeletal painMusculoskeletal and connective tissue disorders3/500/1001/152
Neuropathy peripheralNervous system disorders3/500/1000/152
Dry eyeEye disorders0/505/1001/152

Baseline characteristics

Age, Continuous
Age, Continuous(years)REGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mgTotal
Mean62.5 ± 9.1262.5 ± 10.3659.5 ± 10.2061.0 ± 10.16
Sex: Female, Male
Sex: Female, Male(Participants)REGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mgTotal
Female214968138
Male295184164
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mgTotal
Hispanic or Latino6212653
Not Hispanic or Latino4478125247
Unknown or Not Reported0112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REGN910-3 (3 mg: 2 mg)REGN910-3 (6 mg:2 mg)Aflibercept 2 mgTotal
American Indian or Alaska Native1034
Asian1247
Native Hawaiian or Other Pacific Islander0101
Black or African American1181938
White3787121245
More than one race0000
Unknown or Not Reported0257
08

Study locations

51 sites
  • Mesa, Arizona, United States
  • Tucson, Arizona, United States
  • Arcadia, California, United States
  • Beverly Hills, California, United States
  • Mountain View, California, United States
  • Oceanside, California, United States
  • Palm Desert, California, United States
  • Colorado Springs, Colorado, United States
  • New London, Connecticut, United States
  • Lakeland, Florida, United States
  • Tampa, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Decatur, Georgia, United States
  • 'Aiea, Hawaii, United States
  • Chicago, Illinois, United States
  • New Albany, Indiana, United States
  • Shawnee Mission, Kansas, United States
  • Lexington, Kentucky, United States
  • Portland, Maine, United States
  • Baltimore, Maryland, United States
  • Rockville, Maryland, United States
  • Boston, Massachusetts, United States
  • Grand Rapids, Michigan, United States
  • Jackson, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Florissant, Missouri, United States
  • Las Vegas, Nevada, United States
  • Bloomfield, New Jersey, United States
  • Edison, New Jersey, United States
  • Teaneck, New Jersey, United States
  • Albany, New York, United States
  • Rochester, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Kingston, Pennsylvania, United States
  • Florence, South Carolina, United States
  • West Columbia, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Germantown, Tennessee, United States
  • Nashville, Tennessee, United States
  • Abilene, Texas, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Harlingen, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • The Woodlands, Texas, United States
  • Willow Park, Texas, United States
  • Bellevue, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2016
First posted
Mar 17, 2016
Start
Mar 2, 2016
Primary completionActual
Jul 10, 2017
CompletionActual
Jul 10, 2017
Results first posted
Oct 3, 2018
Last update
Oct 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02712008
Collaborators
Bayer
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
Mar 2, 2016
Primary completion
Jul 10, 2017
Completion
Jul 10, 2017
Results posted
Oct 3, 2018
Last update
Oct 3, 2018

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: REGN910-3 · Aflibercept

Start the discussion